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Abstract
Background Jacobsen syndrome (JS) is a rare contiguous
gene syndrome caused by partial deletion of the long arm of
chromosome 11. Clinical features include physical and mental
growth retardation, facial dysmorphism, thrombocytopenia,
impaired platelet function and pancytopenia. In case reports,
recurrent infections and impaired immune cell function com-
patible with immunodeficiency were described. However,
Jacobsen syndrome has not been recognized as an established
syndromic primary immunodeficiency.
Goal To evaluate the presence of immunodeficiency in a se-
ries of 6 patients with JS.
Methods Medical history of 6 patients with JS was evaluated
for recurrent infections. IgG, IgA, IgM and specific antibodies
against S. pneumoniae were measured. Response to immuni-
zation with a polysaccharide vaccine (Pneumovax) was mea-
sured and B and T lymphocyte subset analyses were
performed using flowcytometry.
Results Five out of 6 patients suffered from recurrent infec-
tions. These patients had low IgG levels and impaired re-
sponse to S. pneumoniae polysaccharide vaccination.
Moreover, we also found a significant decrease in the absolute
number of memory B cells, suggesting a defective germinal
center function. In a number of patients, low numbers of T
lymphocytes and NK cells were found.
Conclusions Most patients with JS suffer from combined im-
munodeficiency in the presence of recurrent infections.
Therefore, we consider JS a syndromic primary immunodefi-
ciency. Early detection of immunodeficiency may reduce the
frequency and severity of infections. All JS patients should
therefore undergo immunological evaluation. Future studies
in a larger cohort of patients will more precisely define the
pathophysiology of the immunodeficiency in JS.
Keywords Immunodeficiency . Jacobsen syndrome . 11q
terminal deletion disorder . humoral . infections
Introduction
Jacobsen syndrome (JS) is a contiguous gene syndrome
caused by partial deletion of the long arm of chromosome
11, and was initially described by the Danish physician dr.
Petra Jacobsen in 1973 [1]. It is a rare disorder with estimated
occurrence of about 1/100,000 births and a female to male
ratio of 2:1 [2–4]. JS is caused by partial deletions of the long
arm of chromosome 11, del(11)(q23) [1]. The deletion size
ranges from 5 to 20 Mb. Breakpoints typically arise within
or distal to subband 11q23.3 and the deletion usually extends
to the telomere. Partial JS with a 5 Mb deletion has been
described as well [2, 5].
The most common clinical features include pre- and post-
natal physical growth retardation, psychomotor retardation,
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behavioural changes, characteristic facial dysmorphism and
thrombocytopenia/thrombocyte dysfunction (Paris-Trousseau
thrombocytopenia with dysmegakaryopoiesis) or pancytope-
nia. A subset of patients has malformations of the heart, kid-
ney, gastrointestinal tract, genitalia, central nervous system
and/or skeleton. Ocular, hearing and endocrine problems
may be present as well [2, 3, 6, 7].
Although JS has not been recognized as a syndromic
primary immune deficiency (SPID) so far, recurrent episodes
of otitis media and/or sinusitis were described in 42 of 78
subjects (54 %) in a prospective study in patients with JS. At
that time, serum IgA levels were evaluated in 13 subjects
and were found to be normal or low normal for age. No
other immunodeficiencies were evaluated in this study [2].
In previous years, several case reports have described the
presence of an immunodeficiency state in patients with JS.
The most important findings in these cases are summarized
in Table 1 [8–12]. Clinical and laboratory features of patient
2,3 and 4 in Table 1 consist of a reduction of all immuno-
globulin subtypes (IgG, IgA and IgM) and impaired re-
sponse to pneumococcal polysaccharide vaccination. These
features are compatible with the primary antibody deficiency
common variable immunodeficiency (CVID). Current diag-
nostic features for CVID, according to the European Society
for Immunodeficiencies (ESID)/Pan American Group for
Immune Deficiency (PAGID) (1999), ESID (2014) and
new diagnostic criteria proposed by Ameratunga et al. [13]
for CVID, include reduction in levels of serum IgG in com-
bination with low levels of IgAwith or without low levels of
IgM, poor or absent response to immunizations and/or low
number of switched memory B cells and an absence of any
other defined immunodeficiency states [14]. Apart from re-
current sinopulmonary tract and gastro-intestinal tract infec-
tions, CVID may also be associated with the development of
auto-immune phenomena and (haematological) malignancies
[15]. Clinical features and additional findings of patients 1, 5
and 6 in Table 1 point towards a combined immunodeficien-
cy, in which B and T lymphocyte and NK cell functions
seem to be impaired.
In summary, these cases suggest that a (primary) immuno-
deficiency is a clinical feature in patients with JS.
In the current study, we evaluated a series of 6 patients
that were randomly recruited from the Dutch JS patient
network with a genetically confirmed diagnosis of JS for
the evaluation of a potential immunodeficiency state.
Medical records were studied to determine whether these
patients suffered from recurrent infections. In addition, im-
munological analyses were performed. We were particular-
ly interested to see whether an immunodeficiency state is
a common feature of JS as suggested by previously pub-
lished case reports. If an immunodeficiency state were
found to be a common feature in JS, then its evaluation
should be performed in all JS patients.
Material and Methods
Patients
This study was conducted in collaboration with the European
Chromosome 11Network (http://11q.chromosome11.eu). The
Jacobsen syndrome patients were informed about the present
study by members of this network. The 12 known Dutch
members with a proven deletion of the long arm of
chromosome 11 were addressed of which 6 patients were
included in this study after obtaining written informed
consent by them or their parents. For this study, Institutional
Review Board approval was obtained (MEC-2013-026,
Erasmus MC, Rotterdam, The Netherlands) and the study
was performed according to the Declaration of Helsinki.
Table 2 shows the demographic and genetic data from the
included JS patients.
Medical History
Patients were invited to visit the Clinical Immunology
Outpatient Clinic at the Department of Internal Medicine,
alone or with (one of) their parents. Medical history was eval-
uated in order to gain insight in the rate, site and severity of
infections in the past. Also the needs for antibiotic treatment
and hospital admission for severe infection were recorded.
Blood Analysis
Blood samples were analysed for serum levels of IgG, IgG-
subclasses, IgA and IgM. Total numbers of B lymphocytes, B
lymphocyte subsets, T lymphocytes and natural killer (NK)
cells were determined by flowcytometry as previously de-
scribed [16]. Specific antibody titres against S. pneumoniae
were analysed using a Luminex assay. The protocol used in
our laboratory was adapted from the protocol as previously
published by Borgers and co-workers [17].
Vaccination Response
As part of the clinical workup for recurrent infections patients
were immunized using a polysaccharide vaccine against
S. pneumoniae (Pneumovax). All patients expect the one pa-
tient (patient 2) with pre-vaccination protective titers, i.e.,
0.35 μg/ml in at least 7 out of 13 measured serotypes (type
1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F,23F) received
Pneumovax vaccine and 4 to 6 weeks after immunization
specific antibody titers against S. pneumonia were measured
and compared to pre-immunization titres. Using a Luminex
assay, an at least 4-fold increase in titres reaching at least
1.00 μg/mL in at least 7 of the 13 measured serotypes 4 to
6 weeks after immunization was determined adequate [18, 19]
using a Luminex assay.
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Results
Clinical Evaluation
In the present study we evaluated 6 patients with a
genetically confirmed diagnosis of JS (see Table 2) for
an immunodeficiency. Five out of our 6 patients (all but
patient number 2 in Table 2) suffered from recurrent
upper and lower respiratory tract infections since early
childhood (otitis, sinusitis and pneumonia) for which
repetitive antibiotic treatments and/or hospital admis-
sions were required. Although only few recorded data
over the past years were available, amongst others
H. influenzae and S. pneumoniae have been cultured
in a number of infectious episodes in these patients.
There were no patients that suffered from recurrent skin,
gastrointestinal tract, or urinary tract infections. Patient
1 however, suffered from multiple and extensive warts
on hands and feet since approximately 3 years, for
which he had received local treatment, without discern-
ible effect. There were no CT scans available from 5
out of 6 patients included, so we could not evaluate
whether any of these patients suffered from bronchiec-
tasis or other lung damage. The CT scan of one patient
did not reveal any structural abnormalities of both
lungs. Two patients were already on immunoglobulin
supplementation therapy when analyzed. Patient 1
started intravenous immunoglobulin supplementation
therapy once every 4 weeks in 2011 at the age of 23.
Patient 6 started subcutaneous immunoglobulin replace-
ment in 2010 at the age of 6. The frequency of infec-
tions decreased after immunoglobulin replacement ther-
apy. There were no signs of auto-immune disease or
lymphoproliferation in any of these patients. There was
no history of malignant diseases.
Initial Evaluation of the Immune System
The results on total numbers of B, T and NK cells and the
levels of IgG, IgA and IgM are summarized in Table 3. In
summary, 5 out of 6 patients showed low levels of IgG. Low
IgA levels were found in 2 and low IgM levels in 5 of the
patients. Total number of B cells were low in 4 out of 6 pa-
tients. Low numbers of T cells and NK cells were found in 2
and 4 patients, respectively. Age-adjusted normal values for
IgG, IgA and IgM and total cell numbers are summarized in
Supplemental Table 1.
Specific Antibody Titres
Five out of 6 patients (patient 1,3,4,5,6) showed inappropriate
responses against Pneumovax. All of these 5 patients also had
low total IgG levels (Table 3).
B Lymphocyte Subset Analysis
By flowcytometry we investigated in more detail the B cell
subsets (Table 4). We determined the absolute numbers of
transitional B-cells (here defined as CD38high/CD24high); na-
ive mature B-cells (CD38dim/CD24dim/IgD+/CD27−); margin-
al zone/natural effector B-cells (CD38dim/IgD+/CD27+) and
memory B-cells (CD38dim/IgD−/CD27+) [20]. As shown in
Table 3, the total number of B cells was low in 4 out of 6
patients studied. In more detail we found a decrease in the
number of memory B cells in 5 out of 6 JS patients. In addi-
tion, marginal zone like B cells were decreased in 4 patients.
Also the total numbers of CD4+ and CD8+ Tcells were low in
1 and 2 patients, respectively. NK cells were below normal
values in 4 patients. Importantly, CD38dimCD27+IgD- mem-
ory B cells in patients with JS were extremely low when
compared to healthy controls (Fig. 1, p<0.05).
Table 2 Age, gender and genetic defects in our 6 patients with Jacobsen syndrome
Patient
number
Age
(years)
Gender Genetic abnormalities Clinical findings
1 24 M 11q- (45, x, ish der) (11) t (y;11) (p11.2;q24.1) (wcpyt)2 Recurrent otitis, sinusitis, upper and lower
respiratory tract infections
2 35 F Deletion 11q (q23.3 – qter) No recurrent infections
3 14 F Deletion 11q (q.24.1-qter) Recurrent otitis, upper and lower respiratory
tract infections
4 14 M Deletion 11q 14.2 – 11q 22.2 Recurrent upper and lower respiratory tract
infections
5 6 F Deletion 11q (q23.3 – qter) Recurrent otitis, sinusitis, upper and lower
respiratory tract infections
6 10 F Deletion 11q (q23.3 – qter) Recurrent otitis, sinusitis, upper and lower
respiratory tract infections
This table shows the age, gender (F = female, M = male) and confirmed genetic abnormalities of the 6 Dutch patients with Jacobsen syndrome studied
764 J Clin Immunol (2015) 35:761–768
Discussion
In the present study 6 patients with confirmed JS were evalu-
ated for the presence of an immunodeficiency state. These
patients had low IgG levels and impaired response to
S. pneumoniae polysaccharide vaccination, defining a specific
polysaccharide antibody deficiency. We also found a reduc-
tion in the number of memory B cells. These features are
compatible with a CVID phenotype. The presence of a
CVID phenotype in JS patients was previously demonstrated
in sporadic cases as well (8–10, Table 1). Moreover, in our
studies we demonstrated that Tand NK cell numbers were low
in a number of JS patients. Although no clinical features were
found compatible with a T cell deficiency, it was recently
reported that a JS patient with a Tcell deficiency suffered from
recurrent viral infections [11]. Recently, newborn screening
for severe combined immunodeficiency (SCID) was
introduced in several countries [21]. SCID is characterized
by a low number of naïve T-cells and in newborn screening
T-cell receptor excision circle (TREC) assay is used to detect
T-cell lymphopenia [22]. Using this approach, patients with JS
were identified shortly after birth, based on abnormal findings
of low TRECS in these patients [21]. These and our findings
of T cell deficiency in 2 out of 6 JS patients suggest that T cell
deficiency may be also a common finding in JS. Finally, we
demonstrated that 4 out of 6 patients had low numbers of NK
cells. Only one patient (patient 1) suffered from infections
(extensive human papilloma virus-induced warts) that may
be due to a NK cell deficiency. In a previous report, genital
and cutaneous condylomata were described in a patient that
showed NK lymphopenia [12]. The presence of B, T and NK
cell abnormalities and recurrent bacterial and viral infections
is compatible with a combined immunodeficiency phenotype,
present in JS.
Table 3 Immunological analysis of 6 patients with Jacobsen syndrome
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
IgG (g/l) 5,8 7,5 5,2 3,1 3,2 3,5
IgA (g/l) 0,45 1,89 0,65 0,30 0,88 0,61
IgM (g/l) <0,30 <0,30 0,97 <0,30 0,17 <0,30
Total number of B-cells (× 109 / l) 0,10 0,05 0,22 0,16 0,09 0,07
Total number of T-cells (× 109 / l) 0,82 0,64 1,38 1,18 0,77 0,48
Total number of NK-cells (× 109 / l) 0,04 0,08 0,23 0,18 0,04 0,04
Specific antibody titers against S. pneumoniae Low Normal Low Low Low Low
Antibody response upon vaccination with
polysacharide vaccin against S. pneumoniae
Decreased Not performed Decreased Decreased Decreased Decresed
This table shows total numbers of B, T and NK cells (all × 109 cells / l) and levels of IgG, IgA and IgM (all in g/l) in 6 patients with Jacobsen syndrome.
All values have been compared to normal values for age and are depicted in italic when normal for age and in bold when low for age. In supplementary
table 1, age-related normal values for total cell numbers and immunoglobulin levels have been summarized
Table 4 Analysis of B and T cell subsets in patients with Jacobsen syndrome
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Total number
of cells, (normal
values adjusted
for age)
Total number
of cells, (normal
values adjusted
for age)
Total number
of cells, (normal
values adjusted
for age)
Total number
of cells, (normal
values adjusted
for age)
Total number
of cells, (normal
values adjusted
for age)
Total number
of cells, (normal
values adjusted
for age)
B-lymphocyte subsets (cells/μl)
Transitional B-cells (CD38high/
CD24high)
11, (3–50) 6, (3–50) 33, (4–108) 24, (4–108) 10, (11–77) 24, (11–77)
Naive mature B-cells (CD38dim/
CD24dim/IgD+/CD27-)
69, (57–447) 33, (57–447) 96, (87–390) 114, (87–390) 69, (111–486) 39, (111–486)
Marginal zone/Natural effector B-cells
(CD38dim/IgD+/CD27+)
8, (9–88) 2, (9–88) 62, (7–90) 12, (7–90) 3, (15–88) 1, (15–88)
Memory B-cells (CD38dim/IgD-/CD27+) 2, (13–122) 2, (13–122) 17, (10–76) 4, (10–76) 5, (13–100) 1, (13–100)
T-lymphocyte subsets (× 109/L)
CD4+ T-lymphocytes 0,2 (0.3–1.4) 0,5 (0.3–1.4) 0,9 (0.4–2.1) 0,7 (0.4–2.1) 0,4 (0.3–2.0) 0,3 (0.3–2.0)
CD8+ T-lymphocytes 0,6 (0.2–1.2) 0,1 (0.2–1.2) 0,4 (0.2–1.2) 0,4 (0.2–1.2) 0,3 (0.3–1.8) 0,2 (0.3–1.8)
Total numbers of various B cell and T cell subsets are presented for the 6 patients with JS. Numbers of cells are presented in cells/μl. Bold numbers
indicate values that are lower than values in age-related healthy control values. In between brackets absolute numbers of cells for age-related healthy
controls are shown
J Clin Immunol (2015) 35:761–768 765
Amongst the most reported infections are otitis and
sinusitis. These were previously thought to be due to ab-
normal facial anatomy and potential chronic Eustachian
tube dysfunction, which is also seen in other genetic syn-
dromes, like trisomy of chromosome 21 (Down syndrome)
[23]. However, over the past decades abnormalities in the
blood B and T cell compartments, decreased IgM, IgG2
and IgG4 levels and poor immunoglobulin response to
vaccinations have been demonstrated in Down syndrome
[24]. Down syndrome is therefore recognized as a SPID
and in recent years various other SPIDs have been identi-
fied, amongst others diGeorge syndrome [25, 26]. These
SPIDs are disorders in which not only the immune system
but also other organ systems are affected and in contrast
to other primary immunodeficiencies, other features than
the immune defects are the presenting symptoms [27]. We
propose that JS should also be considered as a SPID,
based on the susceptibility to infections as well as the
immune cell defects described.
Therefore, close attention should be paid to immune cell
function in these patients and when they present with recurrent
infections immunological evaluation is warranted. It might be
that more patients with JS require immunoglobulin replace-
ment therapy than currently acknowledged. One of the impor-
tant remaining questions is which genetic defect is responsible
for the combined immunodeficiency state in JS. In previous
studies an important role for ETS-1, a member of the ETS
family of transcription factor, was proposed in cardiac abnor-
malities in Jacobsen patients. In mice deletion of ETS-1 leads
to membranous ventricular septal defects, bifid cardiac apex
and a non-apex-forming left ventricle [28]. Moreover, it was
previously found that ETS-1, which is highly expressed in NK
cells, B and T lymphocytes in physiological conditions, is
involved in NK cell development, B cell differentiation and
T lymphocyte development [29–33]. Several aberrations in B
lymphocyte differentiation have been described in ETS-1
knockout mice, like enhanced differentiation into IgM- and
IgG-secreting cells plasma cells and decreased titres of
IgG2a [34, 35]. In mice expressing only one of the 2 known
isoforms of ETS-1 diminished spleen cellularity including
fewer memory cells was found [36]. ETS-1 knockout mice
also have a variety of defects in T cell lineage, including ab-
errant thymic differentiation, reduced peripheral T cell num-
bers, reduced IL-2 production and impairments in Th1 and
Th2 cytokine production [34]. Finally, in ETS-1 deficient
mice lower numbers of NK cells and lower NK progenitors
in the bone marrow are found [37, 38]. Interestingly, in our
study, besides low numbers of memory B cells, low numbers
of total NK cells and T lymphocytes were detected in a num-
ber of patients. This could be explained by a deletion of ETS-
1. On the other hand, Friend Leukemia virus Integration-1
(FLI-1), which belongs to the ETS transcription factor family,
is located on the long arm of chromosome 11 as well and is
mainly expressed in haematopoietic cells. Loss of normal FLI-
1 activation in mice resulted in significantly fewer splenic
follicular B cells, an increased number of transitional and
marginal zone B cells when compared to control mice [39].
There are no studies that have evaluated the role of FLI-1 on
immune cell functions in human. In myeloid malignancies
deletion of 11q was described. Itwas demonstrated that this
deletion existed both as a sole abnormality and in association
with other changes, including t(8;21) [40]. It could therefore
be hypothesized that deletions in the long arm of chromosome
11 in JS coincides with defects on other chromosomes that are
responsible for the immune cell defects described. In ongoing
research we will further characterize which genes in the dele-
tion are responsible for the immune defects in patients with JS.
A larger (international) cohort of JS patients with known ge-
netic defects will be analysed for immunodeficiencies. We
will define the smallest common deletion in JS patients with
proven immunodeficiency, to narrow the potential genes in-
volved in the development of immune cell defects in JS. ETS-
1 may be a candidate gene, but also FLI-1 could play a role
and novel genes with currently unknown function might be
identified as being potentially involved in immune cell func-
tion. The role of FLI-1 on immune cell development and
function will be studied in more detail. Finally, the potential
involvement of genetic defects affecting other chromosomes
should be studied in more detail in JS.
In conclusion, we described for the first time a series
of JS patients with a clinical picture and immunological
abnormalities compatible with a combined immunodefi-
ciency. Based on our findings and previously reported
single cases we propose that JS should be considered as
a SPID and as such should be added to the IUIS classi-
fication of primary immunodeficiencies [41]. Therefore,
immunological screening should be performed in all
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Fig. 1 Total numbers of memory B cells in patients with Jacobsen
syndrome compared to healthy controls. This figure shows the total
numbers of memory B cells in patients with Jacobsen syndrome (n=6)
when compared to the number of memory B cells in healthy individuals
(n=20). A significant (p<0.05) lower number of memory B cells is found
in the patients with Jacobsen syndrome
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patients with a confirmed diagnosis of JS. Early recogni-
tion of immunodeficiency leads to earlier therapeutic inter-
vention, which results in prevention of recurrent infections
and subsequent organ damage.
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distribution, and reproduction in any medium, provided you give
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to the Creative Commons license, and indicate if changes were made.
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